Skip to main content

Monte Rosa

4634 M



Monte Rosa Therapeutics Expands Leadership Team with Appointment of Filip Janku, M.D., Ph.D., as Chief Medical Officer

BOSTON, June 10, 2021 – Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the appointment of Filip Janku, M.D., Ph.D., as the company’s first chief medical officer.

“Our team is excited to welcome Filip on board as we continue to identify disease-causing protein targets that may be amenable to molecular glue-based degradation,” said Markus Warmuth, M.D., CEO of Monte Rosa Therapeutics. “We are looking forward to continuing to advance our programs toward the clinic with Filip’s leadership and expertise.”

Prior to joining Monte Rosa, Dr. Janku served in various roles at The University of Texas MD Anderson Cancer Center, or MD Anderson, including center medical director for the Clinical and Translational Research Center, associate professor and medical oncologist in its Department of Investigational Cancer Therapeutics. There, he specialized in the development of new cancer drugs with a special focus on proof-of-concept studies of novel personalized therapies. Dr. Janku received his M.D. and Ph.D. from Charles University Prague in the Czech Republic.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland. For more information, visit


Katie Engleman

1AB Media